Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein

Artificial intelligence to predict hepatocellular carcinoma risk in cirrhosis

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. The primary risk factor for HCC is cirrhosis. Identifying individuals who are at high risk of developing HCC will have numerous benefits for patient outcomes, patient quality of life, and the global healthcare system. Artificial intelligence (AI) has the capability to develop systems that emulate human intelligence. Recent studies have highlighted the potential of AI in the management of HCC, and the application of AI appears promising for identifying high-risk groups among patients with cirrhosis who require closer monitoring. Ultimately, the aim of AI in the field of HCC clinical care is to enable earlier diagnosis and consequently improve prognosis.